Taken together, we were able to validate three new direct targets for miR-34a-3p, SMAD4, FRAT1 and BCL2, which are likely to be implicated in the deregulation of signaling pathways that are already known to be involved in meningioma genesis and progression. Here, SMAD4 is linked to meningioma.